Compare T Rowe Price Group Inc (TROW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs 10X Genomics Inc — how do they compare? T Rowe Price Group Inc trades at $107.71 (market cap $23.34B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: T Rowe Price Group Inc is far larger — about 2.7× 10X Genomics Inc's market cap, and T Rowe Price Group Inc pays a 4.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TROW | TXG | |
|---|---|---|
Market Cap | $23.34B | $8.55B |
Sector | Financials | Health |
52-Week High | $121.68 | $67.29 |
52-Week Low | $86.19 | $11.34 |
Enterprise Value | $20.54B | $8.08B |
Dividend Yield | 4.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.99, net income margin of 29.26%, and consistent dividend payments. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and significant AI adoption across operations. Revenue has grown from $6.5B in 2022 to $7.3B in 2025, with net income reaching $2.09B.
TROW presents a mixed outlook with attractive valuation metrics and solid profitability offset by bearish technical indicators and equity outflows. The consensus price target of $112.50 suggests modest upside potential. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Institutional buying from firms like BlackRock provides support, but investors should weigh the strong fundamentals against near-term technical weakness.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
